Europe Ocular Pain Market, By Disease Type (Ocular Pain with Eye Diseases and Ocular Pain without Primary Eye Diseases), Type (Diagnosis and Treatment), Application (Conjunctivitis, Corneal Abrasion, Blepharitis, Sty, Iritis, Sinusitis, Migraines, Glaucoma, and Others), Route of Administration (Topical, Periocular, Intraocular, Oral and Others), Drug Type (Prescription and Over the Counter), Population Type (Adults and Geriatric), End User (Hospitals, Specialty Clinics, Home Healthcare Settings, Ophthalmology Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Turkey, and Rest of Europe) – Industry Trends and Forecast to 2028.
Market Analysis and Insights : Europe Ocular Pain Market
Europe ocular pain market is expected to grow in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with a CAGR of 7.0% in the forecast period of 2021 to 2028 and is expected to reach USD 335.30 million by 2028. Increasing unhygienic and sedentary lifestyle acts as a driver for the Europe ocular pain market growth.
Ocular pain also, known as eye pain, commonly occurs due to mild irritation, but it is rarely a symptom of a serious condition. Mostly the pain resolves without medicine or further treatment, and it recovers by the self-immune system. However, ocular pain with underlying primary ophthalmic disorders requires timely treatment. Eye pains are generally categorized under two categories, such as ocular pain, which occurs over the eye's surface, creating sensations of scratching, burning, or itching. They are caused due to a person’s eyelashes, foreign objects, infection, or trauma. Often ocular pain is treated with eye drops and topical steroids or NSAIDs. Ocular pain occurs with underlying primary eye diseases like conjunctivitis, contact lens irritation, corneal abrasion, injury, blepharitis, and sty. The other advanced treatments, like stimulation therapies, are also used for severe neuro ocular pain, appropriately diagnosed.
Increasing unhygienic and sedentary lifestyle, rising prevalence of ophthalmic disorders, and ocular pain act as drivers for the Europe ocular pain market. The increasing awareness among people for eye-related diseases and growing cases of ocular migraine is further boosting the market growth. The side effects of eye treatment medicines and the high cost of eye treatment and medication are restraining the growth of the Europe ocular pain market. Increasing research and development activities, rising healthcare expenditure and disposable income, and growing geriatric population acts as opportunities for the Europe ocular pain market. Lack of healthcare facilities for eye treatment and stringent regulatory framework act as challenges for the Europe ocular pain market growth.
The Europe ocular pain market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the ocular pain market scenario, contact Data Bridge Market Research for an Analyst Brief; our team will help you create a revenue impact solution to achieve your desired goal.
Europe Ocular Pain Market Scope and Market Size
Europe ocular pain market is segmented based on disease type, type, application, route of administration, drug type, population type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of disease type, the Europe ocular pain market is segmented into ocular pain with eye diseases and ocular pain without primary eye diseases. In 2021, the ocular pain with eye diseases segment is expected to dominate the ocular pain market due to high surgical ophthalmic disorder cases.
- On the basis of type, the Europe ocular pain market is segmented into diagnosis and treatment. In 2021, the diagnosis segment is expected to dominate the market as the diagnosis is highly specified for timely treatment options.
- On the basis of application, the Europe ocular pain market is segmented into conjunctivitis, corneal abrasion, blepharitis, sty, iritis, sinusitis, migraines, glaucoma, and others. In 2021, the glaucoma segment is expected to dominate the market as this is the top ophthalmic disorder of the region.
- On the basis of route of administration, the Europe ocular pain market is segmented into topical, periocular, intraocular, oral, and others. In 2021, the topical segment is expected to dominate the market as they provide initial stage treatment for major ophthalmic disorders and ocular pain conditions.
- On the basis of drug type, the Europe ocular pain market is segmented into prescription and over the counter. In 2021, the prescription segment is expected to dominate the market as the community mostly prefers hospital treatment with a proper prescription for safer medications.
- On the basis of population type, the Europe ocular pain market is segmented into adults and geriatric. In 2021, the adults segment is expected to dominate the market due to the rising adult population and boarding students located in the region.
- On the basis of end user, the Europe ocular pain market is segmented into hospitals, specialty clinics, home healthcare, ophthalmology centers, ambulatory surgical centers, and others. In 2021, the hospitals segment is expected to dominate the market due to high technological advancements.
- On the basis of distribution channel, the Europe ocular pain market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others. In 2021, the direct tender segment is expected to dominate the market as the companies directly involve distribution rather than retailers.
Europe Ocular Pain Market Country Level Analysis
Europe ocular pain market is analyzed, and market size information is provided by the country, disease type, type, applications, route of administration, drug type, population type, end user, and distribution channel as referenced above.
The countries covered in the Europe ocular pain market report are the U.K., Germany, France, Spain, Italy, Netherlands, Switzerland, Russia, Turkey, Austria, Ireland, and the Rest of Europe.
The diagnosis segment in the Germany of Europe region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of rising technological advancements. The diagnosis segment in Italy is the second dominating market in the European region due to people's increasingly sedentary lifestyle. France is the third leading market, and the diagnosis segment is expected to dominate here due to increasing awareness of major ocular pain disorders.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of European brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities by Major Market Players to Enhance the Awareness for Ocular Pain Treatment is Boosting the Market Growth of Europe Ocular Pain Market
The ocular pain market also provides you with a detailed market analysis for every country's growth in a particular market. Additionally, it provides detailed information regarding the market players’ strategy and their geographical presence. The data is available for the historical period 2010 to 2019.
Competitive Landscape and Europe Ocular Pain Market Share Analysis
Europe ocular pain market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the Europe ocular pain market.
The major companies dealing in the Europe ocular pain market are Johnson & Johnson Services, Inc., Pfizer Inc., EyePoint Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Akorn Operating Company LLC, AERIE PHARMACEUTICALS, INC., Sun Pharmaceutical Industries Ltd., Bausch & Lomb Incorporated, Ocular Therapeutix, Inc., Novartis AG, Allergan (An AbbVie Company), Sylentis, Pharmaleads SA, OKYO Pharma Limited., Novaliq GmbH and among others are domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many contracts and agreements are also initiated by companies worldwide, which accelerate the Europe ocular pain market.
For instance,
- In March 2021, Sylentis’s dry eye disease product SYL1001_V with tivanisiran ophthalmic solution (eye drops) in their ophthalmology product portfolio has successfully reached phase III clinical trial. This progress is anticipated in launching the product soon after a successful trial, thereby improving their global profile
- In September 2019, Pharmaleads SA participated in International Headache Conference held in Dublin. The company collaborated with Radhouane Dallel, Université de Clermont-Ferrand situated in France, and presented a poster for their clinical results of PL37 product used for acute and chronic migraine pain. This enhanced the company’s global recognition
Collaboration, product launch, business expansion, award and recognition, joint ventures, and other strategies by the market player enhance the company's footprints in the ocular pain market, which also benefits the organization’s profit growth.
SKU-